The discovery of the Ki-67 antibody by Dr. Johannes Gerdes in 1983, with the observation that Ki-67 immunohistochemical expression was only present in proliferating cells, opened the door for considerations about using Ki-67 immunohistochemical expression for the evaluation of breast cancer recurrence risk, as well as for the evaluation of how well patients with breast cancer might respond to chemotherapy. Here, MKI67 is linked to breast carcinoma.